Allogeneic bone marrow transplantation for Fanconi anemia

Area of Science:

• Hematology
• Genetics
• Pediatric Oncology

Background:

• Fanconi anemia (FA) is a rare genetic disorder characterized by progressive pancytopenia and congenital malformations.
• Diagnosis is confirmed through cellular hypersensitivity testing to DNA crosslinking agents like diepoxybutane.
• FA patients often require bone marrow transplantation (BMT) due to bone marrow failure.

Purpose of the Study:

• To evaluate the efficacy and safety of allogeneic bone marrow transplantation (BMT) in pediatric patients with Fanconi anemia (FA).
• To assess the long-term outcomes and survival rates following BMT in FA patients.
• To determine if modified transplant protocols reduce transplant-related complications.

Main Methods:

• Five pediatric patients (7-14 years) with FA underwent allogeneic BMT from HLA-identical siblings.
• Conditioning regimen included low-dose cyclophosphamide and fractionated total body irradiation.
• Graft-versus-host disease prophylaxis involved cyclosporine alone or in combination with methotrexate.

Main Results:

• All five patients survived 18-67 months post-transplant with complete donor-type hematopoiesis and 100% Karnofsky scores.
• Modified transplant protocols led to a reduced incidence of severe transplant-related complications.
• Successful engraftment and sustained normal blood counts were observed in all patients.

Conclusions:

• Allogeneic bone marrow transplantation (BMT) is a curative and effective treatment for Fanconi anemia (FA).
• BMT should be considered the first-line therapy for FA patients with an available HLA-identical sibling donor.
• Optimized BMT protocols enhance patient survival and reduce treatment-related morbidity.